Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q18015294> ?p ?o }
Showing triples 1 to 18 of
18
with 100 triples per page.
- Q18015294 subject Q18071332.
- Q18015294 subject Q18071338.
- Q18015294 abstract "R-HDAC, or R-HD-AraC ((R)ituximab plus (H)igh (D)ose (A)ra-(C)) is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine.High dose Ara-C (HDAC) without rituximab also has several other uses in oncohematology. For example, HDAC, alone or alternating with HD-MTX, is often used for primary CNS lymphoma and for treating CNS involvement in any lymphomas, and also for so-called "CNS prophylaxis" (prophylactic use in those forms of lymphoma which show no signs of CNS involvement at diagnosis but have high chance of CNS relapse or recurrence). HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. HDAC also can be used as the primary induction therapy in AML, with higher than in 7+3 success (remission) rate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary induction therapy.".
- Q18015294 wikiPageWikiLink Q1023650.
- Q18015294 wikiPageWikiLink Q18071332.
- Q18015294 wikiPageWikiLink Q18071338.
- Q18015294 wikiPageWikiLink Q180983.
- Q18015294 wikiPageWikiLink Q208414.
- Q18015294 wikiPageWikiLink Q264118.
- Q18015294 wikiPageWikiLink Q268713.
- Q18015294 wikiPageWikiLink Q3246818.
- Q18015294 wikiPageWikiLink Q412323.
- Q18015294 wikiPageWikiLink Q422248.
- Q18015294 wikiPageWikiLink Q5090632.
- Q18015294 wikiPageWikiLink Q577994.
- Q18015294 wikiPageWikiLink Q79460.
- Q18015294 comment "R-HDAC, or R-HD-AraC ((R)ituximab plus (H)igh (D)ose (A)ra-(C)) is a chemotherapy regimen that is used, alternating with R-Maxi-CHOP, as part of so-called "Nordic protocol" of treating mantle cell lymphoma. It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine.High dose Ara-C (HDAC) without rituximab also has several other uses in oncohematology.".
- Q18015294 label "R-HDAC".